about
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategiesMyelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activityHepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia.Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases.Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.Hormone resistance, invasiveness, and metastatic potential in breast cancer.1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.Functional overlap between two classes of matrix-degrading proteases in wound healingIncorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes.Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia.Role of TPMT and ITPA variants in mercaptopurine disposition.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.The association between glucocorticoid therapy and BMI z-score changes in children with acute lymphoblastic leukemia.Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort.Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial.A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations.Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.Testing physical function in children undergoing intense cancer treatment-a RESPECT feasibility studyClinical features and early treatment response of central nervous system involvement in childhood acute lymphoblastic leukemiaMolecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assaysMetastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient miceAsparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocolCerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemiaAssociation between body mass index and pancreatitis in children with acute lymphoblastic leukemiaThe cost of cureComparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemiaPutative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemiaHepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic reviewBovine Colostrum Against Chemotherapy-Induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Double-Blind, Placebo-Controlled TrialHepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review
P50
Q24671642-3A8C5BB3-267F-41F1-A3BD-9CC7798A9842Q33418418-DE254D30-7CD1-48C8-AA4C-9014C6C60C34Q33441148-2E967D0E-AF65-412D-849B-A75E8EAF30FBQ33557148-F55725FC-9D41-4C76-9D18-1536D222EB93Q39007788-55659CAF-0A86-472A-8A0A-CA3153F03A27Q39571116-8FCC5200-DFF7-4977-81B7-F45D0F210EDCQ40158198-3B376F22-2DC9-46EB-B9D5-A686E79E4454Q40314940-59FD15DF-7D72-45C3-9DC9-0DE4DEABFFA1Q40609832-7D4901DF-758C-431D-B8A8-A1271F60786DQ40877540-D813154F-9B65-4643-894E-6BDF6DA5B6A9Q41469001-897A66FF-6A0C-4CA6-B97D-6831D7835046Q42679931-0127FF6A-D663-445C-9E81-2C42B113BBCDQ43789678-12B8D855-9E0B-47B5-A25C-D60FA9898E98Q43811861-971AEB05-AE3B-4CAB-829E-435666EAC616Q47566809-F94A2A5B-8B6F-45BC-9FC2-F0ADCF57BCEFQ48128079-0CA795D3-B74E-40DE-B419-A9063CF0BF9EQ48203946-E431D8F4-2815-4C36-B6BC-FDF709D9392EQ48234071-D3EC32F9-321F-41E9-BAB4-6EE0AE867CF5Q50561839-9EE56A4A-F088-4CA8-8041-E96DE1029D3DQ50638089-65DD610E-683E-4D56-B94E-F6906E439160Q51530980-116C7B74-471A-43F8-AFF8-182893D11CA9Q51620499-E3500B0C-B802-40B2-8AB3-B055E318099EQ51772466-5F63255B-C4E8-45A8-AE60-758F360494C4Q53662426-0AF78F04-586E-44F5-A547-824FCE87D61BQ55383390-ECB334DD-82FF-401F-AE99-A3C381597960Q57173393-4200FC7C-E004-4F70-AB5F-EA75F7FB4323Q61858162-85FF2CD7-85C1-44A2-BE1F-83E40DD6EB78Q70565921-A82B7EE2-2235-456C-B2A7-D9E439424556Q73646242-D3915584-964C-408C-A5F5-54D4EBCCFCB0Q87104417-609EC600-3EB9-415B-8D53-A7881979EAADQ87613812-62A78E70-4CD8-4326-BC93-28486F7CCCB2Q88395346-96120E57-A76D-4FB0-906A-55E80D4F74ABQ89120035-7C4789BA-AA18-4649-ACB8-15DCDB02CA87Q89255009-BAEDE2C8-0786-460F-BBA9-30251BB1271EQ91136251-E77C0446-BEF9-4128-A32A-6D85EB08813FQ91450471-745A1003-D065-4240-A638-140AA965F864Q92269699-5C854BC9-0295-4DC3-90F8-E766DF44C889Q92300599-7575CF3D-D598-4763-BE94-B11FE25160F6Q95600761-66E9DA50-4177-4EA1-99B6-A5A5B99C938D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas L Frandsen
@ast
Thomas L Frandsen
@en
Thomas L Frandsen
@es
Thomas L Frandsen
@nl
Thomas L Frandsen
@sl
type
label
Thomas L Frandsen
@ast
Thomas L Frandsen
@en
Thomas L Frandsen
@es
Thomas L Frandsen
@nl
Thomas L Frandsen
@sl
prefLabel
Thomas L Frandsen
@ast
Thomas L Frandsen
@en
Thomas L Frandsen
@es
Thomas L Frandsen
@nl
Thomas L Frandsen
@sl
P1053
H-7784-2017
P106
P21
P31
P3829
P496
0000-0001-8495-5274